4.7 Review

Shariant platform: Enabling evidence sharing across Australian clinical genetic-testing laboratories to support variant interpretation

期刊

AMERICAN JOURNAL OF HUMAN GENETICS
卷 109, 期 11, 页码 1960-1973

出版社

CELL PRESS
DOI: 10.1016/j.ajhg.2022.10.006

关键词

-

资金

  1. Australian Genomics (NHMRC) [GNT1113531, GNT2000001]
  2. NHMRC [APP1061779, APP177524]
  3. Victorian Government's Operational Infrastructure Support Program
  4. Royal Children's Hospital Foundation
  5. AmazonWeb Services Cloud Credit for Research grant

向作者/读者索取更多资源

Sharing genomic variant interpretations across laboratories is important for maintaining consistency in variant assertions. However, resource constraints, consent issues, and differences in interpretation systems have hindered the sharing of genotypic data in Australian clinical genetic-testing laboratories. To overcome these barriers, the Shariant platform was developed, enabling ongoing sharing of variant interpretations and associated evidence between laboratories. Through collaboration with clinical laboratories, discrepancies in variant classifications have been identified and efforts to standardize interpretation practices have been made.
Sharing genomic variant interpretations across laboratories promotes consistency in variant assertions. A landscape analysis of Australian clinical genetic-testing laboratories in 2017 identified that, despite the national-accreditation-body recommendations encouraging laboratories to submit genotypic data to clinical databases, fewer than 300 variants had been shared to the ClinVar public database. Consultations with Australian laboratories identified resource constraints limiting routine application of manual processes, consent issues, and differences in interpretation systems as barriers to sharing. This information was used to define key needs and solutions required to enable national sharing of variant interpretations. The Shariant platform, using both the GRCh37 and GRCh38 genome builds, was developed to enable ongoing sharing of variant interpretations and associated evidence between Australian clinical genetic-testing laboratories. Where possible, two-way automated sharing was implemented so that disruption to laboratory workflows would be minimized. Terms of use were developed through consultation and currently restrict access to Australian clinical genetic-testing laboratories. Shariant was designed to store and compare structured evidence, to promote and record resolution of inter-laboratory classification discrepancies, and to streamline the submission of variant assertions to ClinVar. As of December 2021, more than 14,000 largely prospectively curated variant records from 11 participating laboratories have been shared. Discrepant classifications have been identified for 11% (28/260) of variants submitted by more than one laboratory. We have demonstrated that co-design with clinical laboratories is vital to developing and implementing a national variant-interpretation sharing effort. This approach has improved inter-laboratory concordance and enabled opportunities to standardize interpretation practices.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据